Rezolute Inc. (NASDAQ: RZLT) reported interim data from its phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with six ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE